Treace Medical Concepts, Inc. (TMCI) stock
Close on Nov 12, 2026Market cap $347.29MP/E –Yield –
Treace Medical Concepts, Inc. saw revenue fall 7.1% to $203.35M over the twelve months to Sep 30, 2026. Free cash flow was -$18.57M. At the latest close the market valued the company at $347.29M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $347.29M
- P/E ratio
- –
- Price to sales
- 1.71
- Price to book
- 5.63
- Dividend yield
- –
- Free cash flow yield
- -5.35%
Fundamentals
- Revenue
- $203.35M
- Net income
- -$55.79M
- EPS, diluted
- -$0.86
- Free cash flow
- -$18.57M
- Book value per share
- $0.94
- Diluted shares
- 65M
Trading
- Next earnings
- Feb 26, 2027 (estimated, before the open)
- Previous close
- $5.06
- Open
- $5.03
- Day's range
- $4.81 – $5.38
- Volume
- 311,892
- Average volume (20 days)
- 322,132
- Beta (5 years)
- 1.69
- 52-week range
- $1.17 – $5.44
- RSI (14 days)
- 65.6
- Volatility (1 year)
- 83.9%
- Relative volume
- 0.97×
- WACC
- 12.6%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | TMCI | S&P 500 | Difference | TMCI per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +30.2% | -2.7% | +32.9 pts | ||
| 3 months | +12.4% | -1.7% | +14.2 pts | ||
| Year to date | +118.0% | +11.9% | +106.1 pts | ||
| 1 year | +60.6% | +12.0% | +48.6 pts | ||
| 3 years | -14.0% | +78.2% | −92.2 pts | -4.9% | +21.2% |
| 5 years | -75.5% | +73.2% | −148.7 pts | -24.5% | +11.6% |
| 10 years | +81.0% | +309.6% | −228.6 pts | +6.1% | +15.1% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Treace Medical Concepts filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About Treace Medical Concepts
Surgical & Medical Instruments & Apparatus
Treace Medical Concepts, Inc. is a medical technology company focused on advancing surgical treatments for bunions and related midfoot deformities. The company's primary offering is the Lapiplasty 3D Bunion Correction System, which combines specialized instruments, implants, and surgical methods to correct bunion deformities in three planes. Its portfolio also features the Adductoplasty Midfoot Correction System, the Nanoplasty and Percuplasty systems for minimally invasive osteotomies, the SpeedMTP System for great toe fusions, and IntelliGuide pre-operative planning software and cutting guides. Treace Medical Concepts markets these systems to surgical podiatrists, orthopaedic foot and ankle surgeons, ambulatory surgery centers, and hospitals.
Company profile, executives and historyTreace Medical Concepts stock: common questions
What is Treace Medical Concepts's stock price?
TMCI closed at $5.34 on Nov 12, 2026, up 5.53% on the day. Over the past 52 weeks it traded between $1.17 and $5.44.
What is Treace Medical Concepts's market cap?
Treace Medical Concepts was worth $347.29M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is TMCI's P/E ratio?
Treace Medical Concepts lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.86), so it has no meaningful P/E ratio.
How much revenue does Treace Medical Concepts make?
Treace Medical Concepts reported revenue of $203.35M for the twelve months to Sep 30, 2026, down 7.1% from a year earlier.
Does Treace Medical Concepts pay a dividend?
No. Treace Medical Concepts has not paid a cash dividend over the last twelve months.
When does Treace Medical Concepts report earnings next?
Treace Medical Concepts is expected to report Q4 FY2026 results on Feb 26, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has TMCI stock performed over the past year?
Including dividends, TMCI returned +60.6% over the past year, against +12.0% for the S&P 500.
How many TMCI shares are sold short?
2M shares were sold short at the latest FINRA report, 3.82% of the float, or 8.7 days of average trading volume.
Who are Treace Medical Concepts's competitors?
Companies most similar to Treace Medical Concepts by business, industry and size include SIBN, KIDS, LMAT, CARL, SI.
See a number that looks wrong?